GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
PR Newswire —
YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the international journal Vaccine....